A detailed analysis clearly demonstrates increased expression of mdig in early stages of breast cancers and in noninvasive breast cancers, including medullary carcinoma, DCIS and mucinous carcinoma (Fig. 6g, h). Here, RIOX2 is linked to breast carcinoma.